Twist Bioscience (TWST) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Company Overview - Twist Bioscience (TWST) is anticipated to report a year-over-year increase in earnings driven by higher revenues for the quarter ended June 2024, with a consensus outlook suggesting a quarterly loss of $0.79 per share, reflecting a +21.8% change from the previous year [1][3]. Earnings Expectations - The consensus revenue estimate for Twist Bioscience is projected at $77.01 million, which represents a 20.8% increase compared to the same quarter last year [14]. - The consensus EPS estimate has been revised 0.44% higher over the last 30 days, indicating a positive reassessment by analysts [14]. Earnings Surprise Prediction - Twist Bioscience has an Earnings ESP (Expected Surprise Prediction) of +1.68%, suggesting a likelihood of beating the consensus EPS estimate [7][8]. - The company has a strong earnings surprise history, having beaten consensus EPS estimates in the last four quarters [10][18]. Analyst Sentiment - Analysts have recently become more optimistic about Twist Bioscience's earnings prospects, as indicated by the Most Accurate Estimate being higher than the Zacks Consensus Estimate [7]. - The company currently holds a Zacks Rank of 3 (Hold), which may complicate predictions regarding its ability to beat the consensus EPS estimate [12][17]. Industry Context - In the broader context of the Zacks Medical - Biomedical and Genetics industry, other companies like Vertex Pharmaceuticals (VRTX) are also expected to report earnings, with a significant year-over-year decline in EPS estimates [23].